- July 11, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Pulmonology » Pulmonary Diseases » Asthma
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Pulmonology » Pulmonary Diseases » Asthma
Background
Asthma is a chronic inflammatory disease. The severity of asthma varies from a relatively mild, infrequent wheeze to abrupt, life-threatening airway closure. It commonly presents in childhood and is related with characteristics of atopy to hay fever and eczema.
Childhood asthma is a common condition that results in numerous hospital stays and higher healthcare costs. The main characteristic is airway hyperresponsiveness. If left untreated, asthma has a significant fatality rate.
Epidemiology
Asthma affects 15%–20% of people in developed nations and 2–4% in less developed nations. Children are commonly affected. Childhood asthma affects up to 40% of children and is usually reversible. Asthma is more prevalent in populations exposed to cigarette smoke, inhaled particles, and environmental factors.
Asthma is more prevalent in boys during childhood, with a male-to-female ratio of 2:1 until adolescence, then the ratio changes to 1:1. After adolescence, females are more likely to develop asthma, and after age 40, females account for most adult-onset cases.
Due to decreased lung function and airway reactivity, asthma prevalence is higher in older individuals. About 66% of all cases of asthma are diagnosed before the age of 18 years. About 50% of asthmatic children’s symptoms completely resolve after attaining early adulthood.
Anatomy
Pathophysiology
An acute and reversible airway inflammation frequently develops after contact with an environmental trigger. The pathogenic process starts with inhaling an allergen or irritant, such as pollen, which results in airway inflammation and increases mucus production due to bronchial hypersensitivity.
As a result, there is a significant rise in airway resistance, which is most noticeable during expiration. Airway blockage occurs due to inflammatory cell infiltration, hypersecretion with mucus plug development, and smooth muscle contraction.
If asthma is not treated soon, it may deteriorate further because the formation of mucus blocks the inhaled medicine from accessing the mucosa. The swelling from the inflammation becomes worse.
Etiology
Asthma is a disease with a wide range of comprehensive and varied phenotypes. Genetic predisposition, specifically the family history and tendency to allergy, is typically observed as hay fever, eczema, and documented factors associated with asthma.
Asthma has a multi-factorial etiology that is influenced by genetics and environmental exposure, even though the general cause is complicated and still not completely understood, particularly when it comes to predicting that children with pediatric asthma will continue to have asthma in adulthood.
The following factors usually trigger asthma:
Genetics
Prognostic Factors
Asthma causes one mortality per 100,000 individuals, making it a severe condition. Asthma causes missed work and school days and multiple hospitalizations, which increases healthcare costs. Poor asthma control can make the functioning difficult and lower quality of life
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
The treatment paradigm for asthma typically involves a combination of medications, lifestyle modifications, and long-term management strategies. The goal is to achieve and maintain asthma control, reduce symptoms, prevent exacerbations, and improve overall quality of life for individuals with asthma. It’s important to note that while I strive to provide accurate and up-to-date information, treatment approaches may have evolved beyond my knowledge cutoff in September 2021. It’s always best to consult a healthcare professional for the most recent guidelines and recommendations.
Quick-relief medications (short-acting bronchodilators): These are used as needed to relieve acute symptoms and provide immediate relief during asthma attacks. Examples include albuterol (salbutamol) and levalbuterol.
Long-term control medications:
Lifestyle modifications:
Long-term management:
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Allergen Control
Tobacco smoke: Avoid smoking or exposure to secondhand smoke.
Strong odors and chemicals: Use fragrance-free and non-toxic cleaning products, avoid using air fresheners, and limit exposure to strong-smelling chemicals.
Dust mites: Use dust-proof covers on pillows and mattresses, wash bedding regularly in hot water, and keep humidity levels below 50%.
Improve Air Quality
Keep your home clean and free of dust by regular vacuuming, using allergen-proof covers for mattresses and pillows, and washing bedding frequently in hot water.
Consider using air purifiers with HEPA filters to remove airborne allergens. Minimize the use of harsh chemicals, strong perfumes, and cleaning products with strong fumes that may irritate your airways.
Stay informed about the outdoor air quality in your area, especially during times when pollution or allergen levels are high. On days with poor air quality, consider staying indoors or taking precautions like wearing masks designed to filter out allergens or pollutants.
Pet management
If you are allergic to pet dander, it may be necessary to keep pets out of your home or at least restrict them from certain areas like the bedroom. Regularly groom your pets, vacuum upholstered furniture and carpets, and wash bedding that may have come in contact with pet dander.
Use of Beta-Agonists in Acute Exacerbation
Short-acting beta-agonists (SABAs) are the first-line medications used in the acute management of asthma exacerbations. The most commonly used SABA is albuterol (salbutamol). Here’s how beta-agonists are typically used in this situation:
The frequency of beta-agonist administration during an acute exacerbation depends on the severity of symptoms and the individual patient’s response. Initially, a healthcare professional will determine the appropriate dosage and frequency of beta-agonist use. Patients may be advised to administer the medication every 4 to 6 hours as needed, with close monitoring of their symptoms. It is essential for patients to follow the prescribed dosing regimen and seek medical attention if their symptoms worsen or do not improve with medication.
Biologic Agents used for Severe or Poorly Controlled asthma
Biologic agents, also known as biologics or monoclonal antibodies, are a relatively newer class of medications used in the treatment of severe or poorly controlled asthma. These medications specifically target and modulate specific components of the immune system that play a role in asthma inflammation. Biologics can be a beneficial option for individuals who have not achieved adequate control with conventional asthma medications. Here are some commonly used biologic agents for asthma:
Biologic agents are administered through subcutaneous injections, typically every few weeks or months, depending on the specific medication. They are usually prescribed by specialists, such as allergists, pulmonologists, or immunologists, who have experience in managing severe asthma.
Treatment for poorly controlled asthma
When asthma is poorly controlled, the primary goal is to improve symptoms, reduce the frequency and severity of asthma attacks, and enhance overall lung function. Treatment typically involves the use of various pharmaceutical agents, such as:
The administration of these medications depends on the specific agent and the individual’s needs. Inhaled medications are commonly delivered through handheld inhalers or nebulizers. It’s crucial to follow the instructions provided by the healthcare professional or pharmacist for proper administration techniques.
It’s important to work closely with a healthcare professional to determine the most suitable medication and dosage for poorly controlled asthma. They will assess your symptoms, medical history, and lung function tests to develop an individualized treatment plan tailored to your needs.
Administration of a pharmaceutical agent
The medications used in asthma management can be broadly categorized into two main types: long-term control medications and quick-relief medications.
Long-term control medications:
Inhaled Corticosteroids (ICS): These medications are considered the most effective long-term control treatment for asthma in children. They reduce airway inflammation and help prevent asthma symptoms. Examples include beclomethasone, budesonide, fluticasone, and mometasone.
Leukotriene modifiers: These medications block the action of leukotrienes, which are inflammatory chemicals released during an asthma attack. Montelukast is a commonly used leukotriene modifier in pediatric asthma management.
Long-acting beta-agonists (LABAs): These medications relax the muscles around the airways and are often used in combination with inhaled corticosteroids for better asthma control. Common examples include salmeterol and formoterol.
Immunomodulators: In certain cases, pediatricians may consider immunomodulatory agents like omalizumab for children with severe allergic asthma that is not well-controlled with other medications.
Quick-relief medications:
Use of Systemic corticosteroids in severe asthma exacerbations
Systemic corticosteroids are an important treatment option for severe asthma exacerbations in pediatric patients. Severe asthma exacerbations are characterized by a significant worsening of asthma symptoms, including shortness of breath, wheezing, chest tightness, and coughing. These exacerbations can be life-threatening and require prompt medical intervention.
When a child experiences a severe asthma exacerbation, systemic corticosteroids are often prescribed to help reduce airway inflammation and improve lung function. Here are some key points regarding the use of systemic corticosteroids in severe asthma exacerbations:
It is crucial to strictly adhere to the prescribed dosage and duration of systemic corticosteroid treatment. Abrupt discontinuation or improper use of corticosteroids can lead to inadequate control of asthma
Medication
Initial:
6 - 12
mcg
via dry powder inhaler every 12 hours. (Do not exceed 24 mcg/day)
Maintenance: 1 capsule inhaled every 12 hours. (Do not exceed 2 capsules/day)
Metered-dose inhaler: 2 to 4 oral inhalations (45 mcg/actuation) with spacer every 20 minutes for 3 doses
Nebulization solution: 1.25mg to 2.5mg oral inhalation every 20 minutes for 3 doses
Asthma with intermittent symptoms:
Metered-dose inhaler: 2 oral inhalations with a spacer every 4 to 6 hours as needed.
Nebulization solution: 0.63 mg to 1.25 mg oral inhalation every 6 to 8 hours as needed up to 3 doses per 24 hours
for immediate release:
600
mg
Orally
4 times a day
1200 mg twice a day for extended release
40 - 60
mg
Orally
once a day
3 - 10
days
40-60 mg/day orally for 3-10 days
10
mg
Orally
qPM
severe asthma:
3
mg/kg
over 20 to 50 minutes
4
weeks
100
mg
Subcutaneous (SC)
4
weeks
30
mg
Subcutaneous (SC)
4
weeks
first three doses, following every eight weeks thenafter
initial:
2
actuation
of 100 mcg/5 mcg inhaled two times a day and may increase to a higher dose after two weeks; following with 2 actuation of 200 mcg/5 mcg inhaled two times a day
If treatment fails, continue with a Maximum daily dose of 800 mcg/20 mcg
fluticasone furoate and vilanterol
Initial dose:
1 inhalation 100mcg/25mcg or 200mcg/25mcg (fluticasone furoate/vilanterol) once daily
Maximum dose: 1 inhalation 200mcg/ 25mcg (fluticasone furoate/vilanterol) once daily
fluticasone furoate umeclidinium and vilanterol
Initial dose:
1 inhalation of 100 mcg/62.5 mcg/25 mcg or 200 mcg/62.5 mcg/25 mcg (fluticasone/umeclidinium/vilanterol) orally once a day
Maximum dose: 1 inhalation of 200 mcg/62.5 mcg/25 mcg (fluticasone/umeclidinium/vilanterol) once a day
Prophylaxis:
Receiving Bronchodilators: 80 mcg inhaled orally two times a day; may increase to 160 mcg
Receiving Oral Corticosteroids: 80 mcg inhaled orally two times a day; may increase up to 320 mcg
Asthma guidelines: Global Initiative for Asthma guidelines (GINA 2020): HFA inhaler: Metered-dose inhaler:
80-160 mcg required as low dose treatment once a day or in divided doses two times a day
>160-320 mcg required as medium-dose therapy once a day or in divided doses two times a day
>320 mcg required as high-dose therapy once a day or in divided doses two times a day
210
mg
Subcutaneous (SC)
4
weeks
150 - 375
mg
Subcutaneous (SC)
every 2-4 weeks
Mild/moderate/severe:
875
mg
every 12 hrs or 500mg every 8hrs
12.5 - 200
mg
ephedrine/guaifenesin: 1-2 tablets orally 6 times a day as required
Do not exceed 12 tablets a day
25mg/400mg -ephedrine/guaifenesin: 1tablet orally 6 times a day as required
Do not exceed 6 tablets a day
Indicated for Bronchospasm:
20
mg
Tablet
Orally
3 to 4 times a day
Oral inhalation
Solution for nebulization:
Moderate symptoms
0.5 to 1.25mg every 4 hours when needed
Maximum dose-8 inhalations/day
Severe symptoms
2.5 to 5mg inhaled through nebulization of 3 doses for 20 mins maximum
Oral tablets
2.5mg thrice daily
10
mg
Powder
as Spinhaler inhalator
In the case of mild/moderate infections: 500 mg orally every 12 hours or 400 mg intravenously every 12 hours for 7-14 days
In the case of severe/complicated infections: 750 mg orally every 12 hours or 400 mg intravenously every 8 hours for 7-14 days
Limitations for usage: Reserve the fluoroquinolones for patients who are voided of available treatment options for chronic bronchitis
Indicated for Bronchial Asthma
:
Asthmanefrin- whenever needed, take 0.5ml nebulizer solution of 1 to 3 inhalations using the EZ breath atomizer
S2- 0.5 mL of a 2.25 percent solution mixed in 3 millilitres of normal saline via jet nebulizer every three to four hours as needed
For long-term indication, use once daily, as the maintenance of asthma in people more than 12 years
Spiriva Respimat- 2 actuation of 1.25 mcg each, inhaled orally daily
Dose Modifications
In the case of CrCl<50ml/min, use the drug only when the benefits are more than the potential risks
Indicated for Asthma or Reversible Bronchospasm
Nearly 15 mg/kg orally four times a day as needed
Note:
Renal impairment
Sr CrCl >50 ml/min: Reduce 25% of an actual dose
Sr CrCl 10-50 ml/min: Reduce 50% of an actual dose
Sr CrCl <10 ml/min: Reduce 75% of an actual dose
Indicated for mild asthma:
1 to 2 inhalations orally every 4 hours whenever needed.
After the first inhalation, wait for a minute before giving the second puff.
Do not exceed 8 puffs for 24 hours.
Inhalation powder (generic or Advair Diskus): one actuation Orally every 2 times a day; should not exceed more than one actuation, about 50mcg salmeterol /500mcg fluticasone every 2 times a day; should not use with the spacer
Inhalation powder (AirDuo Digihaler, AirDuo RespiClick): One actuation orally every 2 times a day; should not exceed more than one actuation, about 14mcg salmeterol /232mcg fluticasone every 2 times a day; should not use with the spacer or the volume holding chamber.
Inhalation aerosol (Advair HFA): Two actuations Orally every 2 times a day; should not exceed more than two actuations of about 21mcg salmeterol /230mcg fluticasone every 2 times a day
Indicated for the maintenance of asthma
1-2 actuations every 4-6 hours as required
Do not exceed more than 12 actuations each day
Metered dose inhalers propelling chlorofluorocarbons are out of phase
(Discontinued)
Inhaled powder (Treatment for maintenance)
Administer 360 mcg every 12 hours orally.
Some people may start with 180 mcg every 12 hours. Do not exceed 720 mcg every 12 hours.
Patients who require low-dose inhaled corticosteroids: Inhaled once a day, the contents of 1 capsule contain indacaterol 150 mcg and mometasone 80 mcg.
Do not exceed one capsule in a day.
Patients requiring a medium or high dose of inhaled corticosteroid: Inhaled once a day, the contents of 1 capsule contain indacaterol 150 mcg/mometasone 160 mcg or indacaterol 150 mcg/mometasone 320 mcg.
Do not exceed 1 capsule in a day.
Cardiac Glycosides
Take a dose of 600 mg orally daily
Tincture: take a dose of 6 g daily orally divided three times a day
Liquid extract: take a dose of 600 mg daily orally divided three times a day
Dried extract: take a dose 150 mg orally daily
Administer 5 to 10g orally thrice a day
mometasone/glycopyrrolate (glycopyrronium)/ indacaterol
One capsule inhaled orally one time a day
Maximum dose not more than one capsule a day
Dosing modification
Renal Impairment
Dose modification not required
Hepatic impairment
Dose modification not required
The recommended dose is 225 mg twice a day
Take a maintenance dose orally of 4.7 mg/kg in each 8 hours
ciclesonide/formoterol/tiotropium
Indicated for Asthma, chronic obstructive pulmonary disease
160 mcg of ciclesonide/12 mcg of formoterol/18 mcg of tiotropium of one puff one time a day
Indicated for Asthma
Two inhalations four times in a day at the regular interval
Inhaled a dose of 20 mcg up to 4 times daily
Take a dose of 600 to 1800 mg daily in 2 to 3 divided doses
Children >6 years and adolescents <16 years:
12 mcg oral inhalation every 12 hours (Do not exceed 24 mcg/day)
Adolescents >17 years:
Moderate cases: 12 mcg oral inhalation every 12 hours
Severe cases: 24 mcg oral inhalation every 12 hours
Metered-dose inhaler: Children >4 years and Adolescents:
2 oral inhalations every 4 to 6 hours as needed
Nebulization:
Infants and Children <4 years: 0.31 to 1.25 mg oral inhalation every 4 to 6 hours as needed
Children 5 to <12 years: 0.31 to 0.63 mg oral inhalation every 8 hours as needed
Children >12 years and adolescents: 0.63 to 1.25mg oral inhalation every 6 to 8 hours as needed
refer to adult dose
Age: <12 years
1-2 mg/kg orally daily or divided every 12 hours 3-10 days
Age: ≥12 years
40-60 mg/kg orally daily or divided every 12 hours 3-10 days
acute:
0.6
mg/kg
once a day
oral/IV/IM
Age: 6-12 years
40 mg subcutaneous (SC) every 4 weeks
Age: >12 years
100 mg subcutaneous (SC) every 4 weeks
Age: >12 years
30 mg SC 4 weeks for the first three doses, following every eight weeks thenafter
Age: >12 years
Initial: 2 actuation of 100 mcg/5 mcg inhaled two times a day and may increase to a higher dose after two weeks. Continue with 2 actuation of 200 mcg/5 mcg inhaled 2 times a day
If treatment fails, continue with a Maximum daily dose of 800 mcg/20 mcg
Age: >12 years
210 mg SC 4Weeks
<6 years: Safety and efficacy not established
6 to <12 years: 75-375mg subcutaneous every 2-4 weeks
≥12 years: 150-375mg subcutaneous every 2-4 weeks
Mild/moderate/severe :
45 mg/kg daily divided in doses for every 12hrs or 40 mg/kg per day in divided doses for every 8hrs
Age >12 years:
12.5mg/200mg-ephedrine/guaifenesin: 1-2 tablets orally 6 times a day as required
Do not exceed 12 tablets a day
25mg/400mg -ephedrine/guaifenesin: 1tablet orally 6 times a day as required
Do not exceed 6 tablets a day
Indicated for Bronchospasm:
<2 years:0.4mg/kg orally every 8 to 12 hours
2-6 years:1-3.5mg/kg/day divided orally every 6 to 8 hours. Do not exceed 10mg/dose
6-9 hours: 10mg orally 3-4 times daily
>12 years:20mg orally daily thrice
Indicated for bronchial asthma
:
Asthmanefrin:
<4 years: Safety and efficacy not established
≥4 years: whenever needed, take 0.5ml nebulizer solution of 1 to 3 inhalations using the EZ breath atomizer
S2:
<4 years:0.5 mL maximum per dosage, given every 12 hours using a jet nebulizer at 0.05 mL/kg (diluted to 3 mL with NS) over 15 minutes.
≥4 years: 0.5 mL of a 2.25 percent solution mixed in 3 millilitres of normal saline via jet nebulizer every three to four hours as needed
For long-term indication, use once daily, as the maintenance of asthma in people more than 6 years
Spiriva Respimat- 2 actuations of 1.25 mcg each, inhaled orally daily
Less than 2 years old: 0.4 mg/kg orally each 8 to 12 hours
2 to 6 years old: 1 to 3.5 mg/kg daily divided each 6 to 8 hours orally and for each dose maximum dose up to 10 mg
6 to 9 years old: take 10 mg orally three or four times a day
More than 12 years old: take 20 mg orally three times a day
Indicated for the maintenance of asthma
Safety and efficacy are not seen in children below 12 years
For more than 12 years-
1-2 actuation every 4-6 hours as required
Do not exceed more than 12 actuations each day
Metered dose inhalers propelling chlorofluorocarbons are out of phase
(Discontinued)
Inhaled powder (Treatment for maintenance)
<6 years: Safety and efficacy not established
>6 years: Administer 180 mcg every 12 hours orally.
Some people may start with 360 mcg every 12 hours. Do not exceed 360 mcg every 12 hours.
Nebulized suspension
<1 year: Safety and efficacy not established
1 to 8 years (prior treatment with only bronchodilators): Administer 0.5 mg once a day or divided every 12 hours; no more than 0.5 mg per day
1 to 8 years (prior treatment with corticosteroids inhaled): Administer 0.5 mg once a day or divided every 12 hours; no more than 1 mg per day
1 to 8 years (prior treatment with corticosteroids oral): Administer 1 mg once a day or divided every 12 hours; no more than 1 mg per day
Children with symptoms who do not respond to nonsteroidal therapy: Start with 0.25 mg every 12 hours.
Inhaled powder (Treatment for maintenance)
<6 years: Safety and efficacy not established
>6 years: Administer 180 mcg every 12 hours orally.
Some people may start with 360 mcg every 12 hours. Do not exceed 360 mcg every 12 hours.
Nebulized suspension
<1 year: Safety and efficacy not established
1 to 8 years (prior treatment with only bronchodilators): Administer 0.5 mg once a day or divided every 12 hours; no more than 0.5 mg per day
1 to 8 years (prior treatment with corticosteroids inhaled): Administer 0.5 mg once a day or divided every 12 hours; no more than 1 mg per day
1 to 8 years (prior treatment with corticosteroids oral): Administer 1 mg once a day or divided every 12 hours; no more than 1 mg per day
Children with symptoms who do not respond to nonsteroidal therapy: Start with 0.25 mg every 12 hours.
Maintenance therapy
Adolescents and children ≥12 years:
Patients that require a low-dose inhaled corticosteroid with a long-acting beta-agonist:
Inhalation capsule with indacaterol 150 mcg and mometasone 80 mcg:
One capsule's contents should be inhaled once daily;
The daily dose should not exceed: mometasone 320 mcg/150 mcg indacaterol daily.
Patients that require a high-dose inhaled corticosteroid with a long-acting beta-agonist:
Inhalation capsule with indacaterol 150 mcg and mometasone 160 mcg or mometasone 320 mcg/150 mcg indacaterol per day
One capsule's contents should be inhaled once daily;
The daily dose should not exceed: mometasone 320 mcg/150 mcg indacaterol daily.
Indicated for Atopic asthma
Age 6 months-3 years
Initial dose: 0.05 mg/kg orally one to two times a day for five days
Maintenance dose: 0.05 mg/kg orally two times a day
It should not exceed 1 mg two times a day
Age >3 years
Initial dose:1 mg orally one to two times a day for five days
Maintenance dose: 1 mg orally two times a day
for 1 to 9 years old:
Take a maintenance dose orally of 6.2 mg/kg in each 6 hours
for 9 to 16 years old:
Take a maintenance dose orally of 4.7 mg/kg in each 6 hours
Indicated for Asthma
Age >6 years
Two inhalations four times in a day at the regular interval
Future Trends
References
https://www.ncbi.nlm.nih.gov/books/NBK430901/
ADVERTISEMENT
» Home » CAD » Pulmonology » Pulmonary Diseases » Asthma
Asthma is a chronic inflammatory disease. The severity of asthma varies from a relatively mild, infrequent wheeze to abrupt, life-threatening airway closure. It commonly presents in childhood and is related with characteristics of atopy to hay fever and eczema.
Childhood asthma is a common condition that results in numerous hospital stays and higher healthcare costs. The main characteristic is airway hyperresponsiveness. If left untreated, asthma has a significant fatality rate.
Asthma affects 15%–20% of people in developed nations and 2–4% in less developed nations. Children are commonly affected. Childhood asthma affects up to 40% of children and is usually reversible. Asthma is more prevalent in populations exposed to cigarette smoke, inhaled particles, and environmental factors.
Asthma is more prevalent in boys during childhood, with a male-to-female ratio of 2:1 until adolescence, then the ratio changes to 1:1. After adolescence, females are more likely to develop asthma, and after age 40, females account for most adult-onset cases.
Due to decreased lung function and airway reactivity, asthma prevalence is higher in older individuals. About 66% of all cases of asthma are diagnosed before the age of 18 years. About 50% of asthmatic children’s symptoms completely resolve after attaining early adulthood.
An acute and reversible airway inflammation frequently develops after contact with an environmental trigger. The pathogenic process starts with inhaling an allergen or irritant, such as pollen, which results in airway inflammation and increases mucus production due to bronchial hypersensitivity.
As a result, there is a significant rise in airway resistance, which is most noticeable during expiration. Airway blockage occurs due to inflammatory cell infiltration, hypersecretion with mucus plug development, and smooth muscle contraction.
If asthma is not treated soon, it may deteriorate further because the formation of mucus blocks the inhaled medicine from accessing the mucosa. The swelling from the inflammation becomes worse.
Asthma is a disease with a wide range of comprehensive and varied phenotypes. Genetic predisposition, specifically the family history and tendency to allergy, is typically observed as hay fever, eczema, and documented factors associated with asthma.
Asthma has a multi-factorial etiology that is influenced by genetics and environmental exposure, even though the general cause is complicated and still not completely understood, particularly when it comes to predicting that children with pediatric asthma will continue to have asthma in adulthood.
The following factors usually trigger asthma:
Asthma causes one mortality per 100,000 individuals, making it a severe condition. Asthma causes missed work and school days and multiple hospitalizations, which increases healthcare costs. Poor asthma control can make the functioning difficult and lower quality of life
The treatment paradigm for asthma typically involves a combination of medications, lifestyle modifications, and long-term management strategies. The goal is to achieve and maintain asthma control, reduce symptoms, prevent exacerbations, and improve overall quality of life for individuals with asthma. It’s important to note that while I strive to provide accurate and up-to-date information, treatment approaches may have evolved beyond my knowledge cutoff in September 2021. It’s always best to consult a healthcare professional for the most recent guidelines and recommendations.
Quick-relief medications (short-acting bronchodilators): These are used as needed to relieve acute symptoms and provide immediate relief during asthma attacks. Examples include albuterol (salbutamol) and levalbuterol.
Long-term control medications:
Lifestyle modifications:
Long-term management:
Tobacco smoke: Avoid smoking or exposure to secondhand smoke.
Strong odors and chemicals: Use fragrance-free and non-toxic cleaning products, avoid using air fresheners, and limit exposure to strong-smelling chemicals.
Dust mites: Use dust-proof covers on pillows and mattresses, wash bedding regularly in hot water, and keep humidity levels below 50%.
Keep your home clean and free of dust by regular vacuuming, using allergen-proof covers for mattresses and pillows, and washing bedding frequently in hot water.
Consider using air purifiers with HEPA filters to remove airborne allergens. Minimize the use of harsh chemicals, strong perfumes, and cleaning products with strong fumes that may irritate your airways.
Stay informed about the outdoor air quality in your area, especially during times when pollution or allergen levels are high. On days with poor air quality, consider staying indoors or taking precautions like wearing masks designed to filter out allergens or pollutants.
If you are allergic to pet dander, it may be necessary to keep pets out of your home or at least restrict them from certain areas like the bedroom. Regularly groom your pets, vacuum upholstered furniture and carpets, and wash bedding that may have come in contact with pet dander.
Short-acting beta-agonists (SABAs) are the first-line medications used in the acute management of asthma exacerbations. The most commonly used SABA is albuterol (salbutamol). Here’s how beta-agonists are typically used in this situation:
The frequency of beta-agonist administration during an acute exacerbation depends on the severity of symptoms and the individual patient’s response. Initially, a healthcare professional will determine the appropriate dosage and frequency of beta-agonist use. Patients may be advised to administer the medication every 4 to 6 hours as needed, with close monitoring of their symptoms. It is essential for patients to follow the prescribed dosing regimen and seek medical attention if their symptoms worsen or do not improve with medication.
Biologic agents, also known as biologics or monoclonal antibodies, are a relatively newer class of medications used in the treatment of severe or poorly controlled asthma. These medications specifically target and modulate specific components of the immune system that play a role in asthma inflammation. Biologics can be a beneficial option for individuals who have not achieved adequate control with conventional asthma medications. Here are some commonly used biologic agents for asthma:
Biologic agents are administered through subcutaneous injections, typically every few weeks or months, depending on the specific medication. They are usually prescribed by specialists, such as allergists, pulmonologists, or immunologists, who have experience in managing severe asthma.
When asthma is poorly controlled, the primary goal is to improve symptoms, reduce the frequency and severity of asthma attacks, and enhance overall lung function. Treatment typically involves the use of various pharmaceutical agents, such as:
The administration of these medications depends on the specific agent and the individual’s needs. Inhaled medications are commonly delivered through handheld inhalers or nebulizers. It’s crucial to follow the instructions provided by the healthcare professional or pharmacist for proper administration techniques.
It’s important to work closely with a healthcare professional to determine the most suitable medication and dosage for poorly controlled asthma. They will assess your symptoms, medical history, and lung function tests to develop an individualized treatment plan tailored to your needs.
The medications used in asthma management can be broadly categorized into two main types: long-term control medications and quick-relief medications.
Long-term control medications:
Inhaled Corticosteroids (ICS): These medications are considered the most effective long-term control treatment for asthma in children. They reduce airway inflammation and help prevent asthma symptoms. Examples include beclomethasone, budesonide, fluticasone, and mometasone.
Leukotriene modifiers: These medications block the action of leukotrienes, which are inflammatory chemicals released during an asthma attack. Montelukast is a commonly used leukotriene modifier in pediatric asthma management.
Long-acting beta-agonists (LABAs): These medications relax the muscles around the airways and are often used in combination with inhaled corticosteroids for better asthma control. Common examples include salmeterol and formoterol.
Immunomodulators: In certain cases, pediatricians may consider immunomodulatory agents like omalizumab for children with severe allergic asthma that is not well-controlled with other medications.
Quick-relief medications:
Systemic corticosteroids are an important treatment option for severe asthma exacerbations in pediatric patients. Severe asthma exacerbations are characterized by a significant worsening of asthma symptoms, including shortness of breath, wheezing, chest tightness, and coughing. These exacerbations can be life-threatening and require prompt medical intervention.
When a child experiences a severe asthma exacerbation, systemic corticosteroids are often prescribed to help reduce airway inflammation and improve lung function. Here are some key points regarding the use of systemic corticosteroids in severe asthma exacerbations:
It is crucial to strictly adhere to the prescribed dosage and duration of systemic corticosteroid treatment. Abrupt discontinuation or improper use of corticosteroids can lead to inadequate control of asthma
Initial:
6 - 12
mcg
via dry powder inhaler every 12 hours. (Do not exceed 24 mcg/day)
Maintenance: 1 capsule inhaled every 12 hours. (Do not exceed 2 capsules/day)
Metered-dose inhaler: 2 to 4 oral inhalations (45 mcg/actuation) with spacer every 20 minutes for 3 doses
Nebulization solution: 1.25mg to 2.5mg oral inhalation every 20 minutes for 3 doses
Asthma with intermittent symptoms:
Metered-dose inhaler: 2 oral inhalations with a spacer every 4 to 6 hours as needed.
Nebulization solution: 0.63 mg to 1.25 mg oral inhalation every 6 to 8 hours as needed up to 3 doses per 24 hours
for immediate release:
600
mg
Orally
4 times a day
1200 mg twice a day for extended release
40 - 60
mg
Orally
once a day
3 - 10
days
40-60 mg/day orally for 3-10 days
10
mg
Orally
qPM
severe asthma:
3
mg/kg
over 20 to 50 minutes
4
weeks
100
mg
Subcutaneous (SC)
4
weeks
30
mg
Subcutaneous (SC)
4
weeks
first three doses, following every eight weeks thenafter
initial:
2
actuation
of 100 mcg/5 mcg inhaled two times a day and may increase to a higher dose after two weeks; following with 2 actuation of 200 mcg/5 mcg inhaled two times a day
If treatment fails, continue with a Maximum daily dose of 800 mcg/20 mcg
fluticasone furoate and vilanterol
Initial dose:
1 inhalation 100mcg/25mcg or 200mcg/25mcg (fluticasone furoate/vilanterol) once daily
Maximum dose: 1 inhalation 200mcg/ 25mcg (fluticasone furoate/vilanterol) once daily
fluticasone furoate umeclidinium and vilanterol
Initial dose:
1 inhalation of 100 mcg/62.5 mcg/25 mcg or 200 mcg/62.5 mcg/25 mcg (fluticasone/umeclidinium/vilanterol) orally once a day
Maximum dose: 1 inhalation of 200 mcg/62.5 mcg/25 mcg (fluticasone/umeclidinium/vilanterol) once a day
Prophylaxis:
Receiving Bronchodilators: 80 mcg inhaled orally two times a day; may increase to 160 mcg
Receiving Oral Corticosteroids: 80 mcg inhaled orally two times a day; may increase up to 320 mcg
Asthma guidelines: Global Initiative for Asthma guidelines (GINA 2020): HFA inhaler: Metered-dose inhaler:
80-160 mcg required as low dose treatment once a day or in divided doses two times a day
>160-320 mcg required as medium-dose therapy once a day or in divided doses two times a day
>320 mcg required as high-dose therapy once a day or in divided doses two times a day
210
mg
Subcutaneous (SC)
4
weeks
150 - 375
mg
Subcutaneous (SC)
every 2-4 weeks
Mild/moderate/severe:
875
mg
every 12 hrs or 500mg every 8hrs
12.5 - 200
mg
ephedrine/guaifenesin: 1-2 tablets orally 6 times a day as required
Do not exceed 12 tablets a day
25mg/400mg -ephedrine/guaifenesin: 1tablet orally 6 times a day as required
Do not exceed 6 tablets a day
Indicated for Bronchospasm:
20
mg
Tablet
Orally
3 to 4 times a day
Oral inhalation
Solution for nebulization:
Moderate symptoms
0.5 to 1.25mg every 4 hours when needed
Maximum dose-8 inhalations/day
Severe symptoms
2.5 to 5mg inhaled through nebulization of 3 doses for 20 mins maximum
Oral tablets
2.5mg thrice daily
10
mg
Powder